Prognostic Significance of Matrix Metalloproteinase-7 in Gastric Cancer Survival: a Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Apr 29

PMID 25919283

Citations 17

Authors

Saeed Soleyman-Jahi

Saharnaz Nedjat

Afshin Abdirad

Niloofar Hoorshad

Reza Heidari

Kazem Zendehdel

Affiliations

Soon will be listed here.

Abstract

The prognostic role of matrix metalloproteinase-7 in gastric cancer survival has been widely evaluated. However, the results are controversial. We aimed to set up a meta-analysis to reach a conclusion on the prognostic significance of metalloproteinase-7 in gastric cancer survival as well as its association with clinicopathological parameters. We searched popular databases from 1988 until October 2014 to gather eligible peer-reviewed papers addressing the prognostic effect of matrix metalloproteinase-7 in gastric cancer patients' survival. The CASP check list was used for quality appraisal. Pooled hazard ratio (HR) for survival and odds ratio (OR) for association with their 95% confidence interval (CI) were considered as summary measurements. Finally, 1208 gastric cancer patients from nine studies were included in the meta-analysis. Pooled HR estimate for survival was 2.01 (95% CI = 1.62 - 2.50, P < 0.001), which indicated a significant poor prognostic effect for matrix metalloproteinase-7. Sensitivity analysis detected no dominancy for any study. No publication bias was detected according to Egger's and Begg's tests. Clinicopathological assessment revealed that higher matrix metalloproteinase-7 expression is associated with deeper invasion (pooled OR = 3.20; 95% CI = 1.14 - 8.96; P = 0.026), higher TNM stage (pooled OR = 3.67; 95% CI = 2.281-5.99; P<0.001), lymph node metastasis (pooled OR = 2.84; 95% CI = 1.89 - 4.25; P<0.001), and distant metastasis (pooled OR = 3.68; 95% CI = 1.85 - 7.29; P<0.001), but not with histological grade. This meta-analysis indicated a significant poor prognostic effect of matrix metalloproteinase-7 in gastric cancer survival. Additionally it was associated with aggressive tumor phenotype.

Citing Articles

Unveiling molecular clues: Exploring IFNγ, IL-10, and MMP7 blood levels in gastric carcinoma patients.

Atul A, Palanivelu Elamurugan T, Sudharsanan S, Vijayakumar C, Shamanna Sreenath G, Balasubramaniyan V Turk J Surg. 2025; 40(3):212-218.

PMID: 39917407 PMC: 11792898. DOI: 10.47717/turkjsurg.2024.6421.

Comprehensive investigation of matrix metalloproteinases in skin cutaneous melanoma: diagnostic, prognostic, and therapeutic insights.

Wu L, Liu C, Hu W Sci Rep. 2025; 15(1):2152.

PMID: 39820824 PMC: 11739484. DOI: 10.1038/s41598-025-85887-2.

Clinicopathological features and cancer transcriptomic profiling of poorly cohesive gastric carcinoma subtypes.

Yen H, Chen P, Huang R, Jeng J, Lai I J Pathol Clin Res. 2024; 10(4):e12387.

PMID: 38860888 PMC: 11165978. DOI: 10.1002/2056-4538.12387.

Identification of Hub Genes and Potential Pathogenesis in Gastric Cancer Based on Integrated Gene Expression Profile Analysis.

Luu Truong Thanh H, Hoang T, Hoang Van H Asian Pac J Cancer Prev. 2024; 25(3):885-892.

PMID: 38546071 PMC: 11152393. DOI: 10.31557/APJCP.2024.25.3.885.

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.

van den Ende N, Nguyen A, Jager A, Kok M, Debets R, van Deurzen C Int J Mol Sci. 2023; 24(3).

PMID: 36769287 PMC: 9918290. DOI: 10.3390/ijms24032969.

References

Shen W, Xi H, Wei B, Chen L . The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J Cancer Res Clin Oncol. 2014; 140(6):1003-9. DOI: 10.1007/s00432-014-1630-6. View

Qian Q, Wang Q, Zhan P, Peng L, Wei S, Shi Y . The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010; 28(6):661-9. DOI: 10.3109/07357901003735634. View

Brinckerhoff C, Matrisian L . Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002; 3(3):207-14. DOI: 10.1038/nrm763. View

Pajouh M, Nagle R, Breathnach R, FINCH J, Brawer M, Bowden G . Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol. 1991; 117(2):144-50. DOI: 10.1007/BF01613138. View

Butler G, Overall C . Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov. 2009; 8(12):935-48. DOI: 10.1038/nrd2945. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Koskensalo S, Mrena J, Wiksten J, Nordling S, Kokkola A, Hagstrom J . MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010; 31(3):149-55. DOI: 10.1007/s13277-010-0020-1. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K . Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer. 2002; 3(2):63-70. DOI: 10.1007/pl00011698. View

10.

Wang W, Chen P, Wang H, Liang W, Su Y . Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis. 2006; 27(5):1113-20. DOI: 10.1093/carcin/bgi351. View

11.

Hadler-Olsen E, Winberg J, Uhlin-Hansen L . Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 2013; 34(4):2041-51. DOI: 10.1007/s13277-013-0842-8. View

12.

Woessner Jr J, Taplin C . Purification and properties of a small latent matrix metalloproteinase of the rat uterus. J Biol Chem. 1988; 263(32):16918-25. View

13.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

14.

Li Z, Zhang D, Zhang H, Miao Z, Tang Y, Sun G . Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients. Tumour Biol. 2013; 35(4):3463-70. DOI: 10.1007/s13277-013-1458-8. View

15.

Davies B, Brown P, East N, Crimmin M, Balkwill F . A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993; 53(9):2087-91. View

16.

Vihinen P, Kahari V . Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002; 99(2):157-66. DOI: 10.1002/ijc.10329. View

17.

Szarvas T, Jager T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I . Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res. 2011; 17(2):325-32. DOI: 10.1007/s12253-010-9320-4. View

18.

Kubben F, Sier C, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde C . Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer. 2006; 94(7):1035-40. PMC: 2361233. DOI: 10.1038/sj.bjc.6603041. View

19.

Blanco-Calvo M, Tarrio N, Reboredo M, Haz-Conde M, Garcia J, Quindos M . Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer. Future Oncol. 2014; 10(7):1187-202. DOI: 10.2217/fon.13.263. View

20.

Williamson P, Tudur Smith C, Hutton J, Marson A . Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002; 21(22):3337-51. DOI: 10.1002/sim.1303. View